Abstract
RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.
Funding Information
  • NIH Office of the Director (HL81753)
  • NIH Office of the Director (HL107304)
  • NIH Office of the Director (HL111437)
  • NIH Office of the Director (GM63904)
  • American Heart Association (14SDG18160021)

This publication has 45 references indexed in Scilit: